Vitrified-warmed blastocyst transfer on the 5th or 7th day of progesterone supplementation in an artificial cycle: a randomised controlled trial

Autor:	H. Tournaye, L. Van Landuyt, Samuel Santos-Ribeiro, N.P. Polyzos, Panagiotis Drakopoulos, Christophe Blockeel, A. van de Vijver, Shari Mackens, Veerle Vloeberghs
Přispěvatelé:	Faculty of Medicine and Pharmacy, Surgical clinical sciences, Reproduction and Genetics, Reproductive immunology and implantation, Gyneacology-Urology, Biology of the Testis
Rok vydání:	2017
Předmět:	Adult medicine.medical_specialty Pregnancy Rate Endocrinology Diabetes and Metabolism Biology Group B law.invention Andrology 03 medical and health sciences 0302 clinical medicine Endocrinology Randomized controlled trial Pregnancy law Menstrual Cycle/drug effects medicine Humans Embryo Implantation 030212 general & internal medicine Blastocyst Embryo Transfer/methods Menstrual Cycle Progesterone Gynecology 030219 obstetrics & reproductive medicine Blastocyst Transfer Infant Newborn Obstetrics and Gynecology Embryo Transfer medicine.disease Progesterone/therapeutic use Vitrification Embryo transfer Pregnancy rate medicine.anatomical_structure Oocyte donation Embryo Implantation/drug effects Female
Zdroj:	Gynecological Endocrinology. 33:783-786
ISSN:	1473-0766 0951-3590
DOI:	10.1080/09513590.2017.1318376
Popis:	Prospective studies comparing different durations of progesterone supplementation before transfer of vitrified-warmed blastocysts in an artificial cycle are lacking. However, in oocyte donation programmes, the sporadic available evidence demonstrates considerable differences in clinical pregnancy rates according to the duration of progesterone administration. This randomised controlled trial (RCT), included 303 patients undergoing a frozen-thawed embryo transfer (FET) of one or two vitrified-warmed blastocyst(s) in an artificial cycle. Randomisation was performed when the endometrial thickness reached ≥7 mm after oestrogen supplementation. One hundred and fifty two patients in group A received 7 d of vaginal micronised progesterone tablets and 151 patients in group B received 5 d of micronised vaginal progesterone before FET. No differences were seen in clinical pregnancy rate between both groups: 42/152 (27.6%) in group A versus 49/151 (32.5%) in group B. Although no statistically significant difference was observed in clinical pregnancy rates, our study was powered to detect an absolute difference of 16%. In this regard, we cannot exclude that smaller, clinically relevant differences might exist and our study did not have the power to detect this. Patients were also not blinded for the intervention, causing a potential bias.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f23dcaf1b6a4c12690f1690552f729 https://doi.org/10.1080/09513590.2017.1318376 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.